Your fact-checks will appear here
Family name
The Johnson & Johnson (Janssen) COVID‑19 vaccine has been linked to very rare, serious adverse events—primarily vaccine‑induced thrombosis with thrombocytopenia (VITT/TTS) and rare reports of Guillain...
Known long-term or delayed serious adverse events tied to the Johnson & Johnson (Janssen) COVID‑19 vaccine are rare and limited mainly to two clotting and neurologic syndromes — thrombosis with thromb...
Public, consumer-facing lot‑number lookup tools exist for some COVID‑19 vaccines (for example Moderna’s Vial Lookup and manufacturer/Janssen checkers), but Pfizer (Comirnaty/BNT162b2) does not maintai...
Large surveillance studies and safety summaries show different rare long‑term risks for the Janssen (J&J) adenovirus vaccine versus mRNA vaccines: J&J has been associated with rare thrombosis with thr...
Pfizer and Moderna mRNA vaccines produce (injection-site pain, fatigue, headache, fever) that are generally mild and resolve in days, with likely due to a higher mRNA dose . Rare serious events differ...
Clinical surveillance through 2022–2025 finds , with Janssen linked more to thrombosis with thrombocytopenia syndrome (TTS) and Guillain-Barré syndrome (GBS), and mRNA vaccines showing higher signals ...
directs readers to each ’s fact sheet or package insert for the definitive list of ingredients and notes that those documents contain the full ingredient disclosures . Public summaries compiled by sta...
The Johnson & Johnson (Janssen) COVID-19 vaccine has been linked to a very small number of rare but serious adverse events—most notably vaccine‑induced thrombotic thrombocytopenia (TTS, also called VI...
Regulatory agencies and multiple studies since 2021 have linked a very small number of neurological and immune-mediated conditions to the Janssen/Johnson & Johnson (J&J) adenoviral‑vector COVID‑19 vac...
Available reporting links Johnson & Johnson’s (J&J/Janssen) adenovirus‑vector COVID‑19 vaccine to a rare syndrome—thrombosis with thrombocytopenia syndrome (TTS)—with roughly 57–60 reported U.S. cases...
mRNA COVID-19 vaccines can trigger short-lived changes in immune markers and—in rare cases—cause inflammatory conditions such as myocarditis; major public-health reviews and cohort studies find no sus...
Available reporting and official guidance do not describe the Janssen (Johnson & Johnson) COVID-19 vaccine as a substance the body “expels” on a defined timetable; rather, it is an intramuscular viral...
Routine blood tests can show transient immune activation after mRNA COVID-19 vaccination — most commonly temporary rises in inflammatory markers and antibody levels as part of the intended immune resp...
Since 2020, illicit fentanyl production has shifted through three measurable trends: clandestine chemistry diversified from older Janssen/Siegfried routes toward “one‑pot” and Gupta‑style methods that...
The preponderance of reports from 2021–2025 shows that the . Large passive-safety datasets and narrative reviews agree that serious neurological adverse events are uncommon relative to vaccine doses a...
Regulatory agencies and medical literature link the Johnson & Johnson/Janssen COVID-19 vaccine to a small but measurable increase in a few specific autoimmune-type disorders, most notably Guillain-Bar...
The available evidence shows the FDA did issue safety updates and revised fact sheets for the Janssen (Johnson & Johnson) COVID‑19 vaccine in earlier years (2021–2023) adding warnings for rare but ser...
Reports and peer-reviewed reviews link several rare, long-term neurological syndromes to COVID-19 vaccination in general — most commonly Guillain-Barré syndrome (GBS), functional neurological disorder...
Regulatory reviews and surveillance from 2021 onward identified a small number of rare but serious adverse events after the Janssen (Johnson & Johnson) COVID-19 vaccine — chiefly thrombosis with throm...
Up to and through 2024, the Johnson & Johnson (Janssen, Ad26.COV2.S) COVID-19 vaccine has been linked to a small number of rare but serious adverse events — most notably thrombosis with thrombocytopen...